Compare BioNano Genomics Inc (BNGO) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Boston Beer Company Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Boston Beer Company Inc trades at $171.79 (market cap $1.76B). The key difference: Boston Beer Company Inc is far larger — about 133.3× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | SAM | |
|---|---|---|
Market Cap | $13.20M | $1.76B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $260.05 |
52-Week Low | $1.09 | $161.08 |
Enterprise Value | $15.81M | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Boston Beer Company (SAM) trades at $172.39, down 2.49% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, but faces headwinds with negative 2026 profit margin projections. Recent news highlights innovation in Beyond Beer products and marketing initiatives, though Q1 2026 earnings missed expectations and volume growth concerns persist.
The stock presents a cautious opportunity with analyst consensus target of $213.50 offering 24% upside, but investors face risks from declining volumes, margin pressure, and competitive threats. While cash flow remains positive and valuation ratios appear reasonable, the negative 2026 earnings outlook and bearish technical momentum warrant careful monitoring of upcoming Q2 results and brand performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
